Detalles de la búsqueda
1.
Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.
Cancer
; 130(9): 1600-1608, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38100492
2.
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
N Engl J Med
; 382(7): 597-609, 2020 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31825569
3.
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Breast Cancer Res Treat
; 199(3): 457-469, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37061619
4.
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.
Clin Immunol
; 225: 108679, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33485895
5.
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
Oncologist
; 25(6): e909-e919, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32003919
6.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Lancet Oncol
; 20(6): 816-826, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31047803
7.
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
Br J Cancer
; 120(12): 1105-1112, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31097774
8.
Initial safety analysis of a randomized phase II trial of nelipepimut-Sâ¯+â¯GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.
Clin Immunol
; 201: 48-54, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30817999
9.
Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Oncologist
; 24(3): 313-318, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30139836
10.
Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).
Breast Cancer Res Treat
; 176(1): 227-234, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30977027
11.
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
Oncologist
; 23(11): 1300-1309, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30139837
12.
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-ß.
Invest New Drugs
; 36(6): 1103-1109, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30311036
13.
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.
Invest New Drugs
; 36(2): 299-306, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29374384
14.
Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer.
J Natl Compr Canc Netw
; 16(5): 518-524, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29752326
15.
Outcomes of children exposed in utero to chemotherapy for breast cancer.
Breast Cancer Res
; 16(6): 500, 2014 Dec 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25547133
16.
Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.
Cancer
; 120(13): 1932-8, 2014 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24677057
17.
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.
Clin Cancer Res
; 29(1): 174-182, 2023 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36074155
18.
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.
JAMA Oncol
; 9(2): 197-205, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36454580
19.
Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial.
Cancers (Basel)
; 15(13)2023 Jun 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37444385
20.
PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens.
Ther Adv Med Oncol
; 15: 17588359231189422, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37547448